Table 2.
IPD incidence rates ratio as % change in children with HbSS, SCD (HbSS/SC), or reference population, comparing periods
| Outcome/serotypes | Population | Age, y | IPD incidence rate ratio as % change∗ (95% CI), P value |
||
|---|---|---|---|---|---|
| PCV7 vs pre-PCV period |
PCV13 vs PCV7 period |
PCV13 vs pre-PCV period |
|||
| 2000-2009 vs 1994-1999 | 2010-2018 vs 2000-2009 | 2010-2018 vs 1994-1999 | |||
| All IPD | HbSS | 0-4 | 63.4 (37.0-78.7), <.001 | 66.0 (26.6-84.3), .006 | 87.6 (73.8-94.1), <.001 |
| 5-9 | 63.1 (9.1-85.0), .030 | 46.2 (−33.8 to 80.9), .239 | 80.1 (45.4-92.8), .002 | ||
| 0-9 | 64.7 (43.8-77.8), <.001 | 60.9 (27.8-78.8), .003 | 86.2 (75.0-92.4), <.001 | ||
| HbSC | 0-4 | 95.4 (63.8-99.4), .003 | −69.1 (−96.5 to 63.9), .294 | 85.0 (52.2-95.3), .001 | |
| 0-9 | 87.4 (54.3-96.5), .002 | −9.1 (−79.7 to 75.4), .900 | 86.2 (55.8-95.7), <.001 | ||
| HbSS/SC | 0-4 | 71.6 (52.9-82.9), <.001 | 54.0 (9.7-76.6), .024 | 86.9 (75.6-93.0), <.001 | |
| 5-9 | 55.8 (−3.9 to 81.2), .062 | 55.5 (−17.0 to 83.5), .111 | 80.3 (45.8-92.8), .002 | ||
| 0-9 | 69.6 (53.1-80.2), <.001 | 54.9 (21.1-74.2), .005 | 86.3 (76.7-91.9), <.001 | ||
| Reference | 0-4 | 72.7 (69.7-75.4), <.001 | 67.9 (62.0-72.8), <.001 | 91.2 (89.7-92.5), <.001 | |
| 5-9 | 54.2 (35.5-67.4), <.001 | 49.1 (23.3-66.2), .001 | 76.7 (64.9-84.5), <.001 | ||
| 0-9 | 72.1 (69.2-74.8), <.001 | 65.9 (60.1-70.8), <.001 | 90.5 (89.0-91.8), <.001 | ||
| Meningitis | HbSS | 0-9 | 47.0 (−42.4 to 83.8), .294 | 86.1 (−13.4 to 98.3), .068 | 92.6 (37.0-99.1), .017 |
| Reference | 0-9 | 50.0 (19.1-69.2), .005 | 51.9 (14.0-73.2), .014 | 76.0 (56.8-86.7), <.001 | |
| Death | HbSS | 0-9 | 92.6 (38.9-99.1), .016 | 16.6 (−92.5 to 94.8), .898 | 93.9 (49.0-99.3), .010 |
| Reference | 0-9 | 63.1 (18.6-83.2), .013 | 56.3 (−20.5 to 84.8), .125 | 83.9 (55.2-94.2), <.001 | |
| PCV13∗ | HbSS/SC | 0-9 | 68.4 (21.4-87.3), .013 | 100.0 (62.2 to 100.0), ∗∗0.004 | 100.0 (91.9 to 100.0), ∗∗<.001 |
| Reference | 0-9 | 18.6 (−2.7 to 35.5), .084 | 73.7 (64.4-80.6), <.001 | 78.6 (70.4-84.6), <.001 | |
| Non-PCV13 | HbSS/SC | 0-9 | −59.4 (−88.1 to 27.8), .150 | 16.9 (−38.6 to 57.6), .590 | −51.2 (−85.7 to 40.0), .252 |
| Reference | 0-9 | −39.0 (−57.3 to 12.9), .006 | 14.5 (−8.5 to 33.1), .210 | −28.7 (−50.3 to 2.3), .067 | |
| 15B/15C | HbSS/SC | 0-9 | 34.8 (−74.4 to 89.1), .640 | −9.8 (−79.8 to 75.2), .893 | 27.7 (−74.7 to 86.8), .708 |
| Reference | 0-9 | −63.0 (−87.2 to 6.5), .066 | 20.6 (−31.4 to 56.8), .457 | −53.4 (−84.1 to 27.0), .165 | |
For incidence rate ratio (IRR) of <1: % change = (1 − IRR) × 100; for IRR of ≥1: % change = (1 − 1/IRR) × 100.
∗
Non-PCV7 serotypes.
∗∗
Conditional maximum likelihood estimate of Rate Ratio; https://www.openepi.com